Cencora stock target raised to USD 377 ahead of earnings

An analyst raised the price target for Cencora ahead of the company's fiscal fourth-quarter results, adding a fresh valuation signal before the scheduled report. Transcript Daily reported the target at USD 377 in an article published Monday, November 2, 2026. The report also cited a Moderate Buy consensus among analysts.

Cencora stock traded at EUR 294.30 on Lang & Schwarz at 11:46 CET on Monday, November 2, 2026. Investors can follow the real-time quote of Cencora stock for the latest trading indication.

Earnings take center stage

Cencora plans to release its fiscal fourth-quarter and full-year fiscal 2026 results before trading begins on the New York Stock Exchange on Wednesday, November 4. The company said the results call will start at 8:30 a.m. Eastern Time, with Chief Executive Officer Robert P. Mauch and Chief Financial Officer Eva C. Boratto scheduled to participate.

The earnings release is the next major test for the pharmaceutical distribution and healthcare-solutions group. Investors are likely to focus on the outlook for fiscal 2027, operating performance in the US and international businesses, and the effect of specialty pharmaceutical demand on margins. The company has not yet released the fiscal fourth-quarter figures.

The target move gives investors a reference point ahead of the report but does not determine the outcome of the earnings release. The analyst action should therefore be weighed against the company's forthcoming results and management's comments rather than viewed as a substitute for operating performance.

The S&P 500 provides the relevant US market context for this US-listed stock.

Further company updates are available in more news and analyses on Cencora stock.

Key facts

Transcript Daily reported the analyst target change, while Cencora's investor-relations announcement confirmed the earnings schedule.